After IS-tumor establishment, spheropatients were randomized and treated with a dose of trametinib (1 mg/Kg/die) previously shown to be well tolerated and effective in xenograft models harboring BRAF mutation (Fig. 5c)37,41. Here, BRAF is linked to neoplasm.